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Abstract 
Interleukin-1 (IL-I) in combination with other cytokines can induce a reproducible r lease of collagen fragments from 
bovine nasal cartilage in culture. Over 70% of the total collagen is released by day 14 and this release is accompanied by 
the appearance of collagenolytic activity in the medium that cleaves collagen specifically at the one quarter/three quarter 
position. Interleukin-4 is able to prevent he release of collagen fragments from the tissue and this is accompanied by a 
reduced secretion and activation of collagenase (MMP-1) with an increase in tissue inhibitor of metalloproteinases-1 
(TIMP-1). IL-4, especially in the presence of IL-1, increased TIMP secretion by bovine nasal cartilage in culture. These 
results suggest hat IL-4 is able to specifically block cartilage collagen resorption by down-regulating the production of 
collagenase (MMP-1) and up-regulating TIMP-1 by chondrocytes within the cartilage. 
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1. Introduction 
The matrix metalloproteinases (MMPs) are a fam- 
ily of zinc-containing proteinases that can degrade all 
the components of the extracellular matrix. These 
potent enzymes are controlled at a number of key 
points that include the stimulation of synthesis and 
secretion by cytokines and growth factors, the pro- 
Abbreviations: IL-I, interleukin-l; GAG, glycosaminoglycan; 
MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of met- 
alloproteinases-1; TNFa, tumour necrosis factor a; APMA, 
amino phenyl mercuric acetate; IL-4, interleukin 4; OM, Onco- 
statin M; IFNy, interferon gamma 
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duction of proenzyme forms requiring activation and 
the inhibition by naturally occurring inhibitors [1]. 
The tissue inhibitor of metalloproteinases (TIMPs), 
only inhibit MMPs forming 1:1 stoichiometric com- 
plexes with the active forms of all MMPs [2]. 
Three MMPs, fibroblast collagenase; MMP-1 [3], 
neutrophil collagenase; MMP-8 [4] and collagenase-3; 
MMP-13 [5], can all specifically cleave triple helical 
collagen to give characteristic 3 /4  and 1 /4  products. 
MMP-1 consists of two domains linked by an ex- 
posed proline-rich linking peptide [6]. Whilst the 
N-terminal domain contains the active site zinc, the 
C-terminal domain is important in substrate binding. 
MMP-1 is known to be present within the rheumatoid 
joint [7], it can be localised to rheumatoid synovial 
tissue [8] and is upregulated by the proinflammatory 
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cytokines interleukin-1 (IL-1) and tumour necrosis 
factor-a (TNFot) [9,10] s.uggesting its importance in 
the breakdown of cartilage collagen in arthritic dis- 
eases. 
Cartilage is composed of collagen and proteogly- 
can and low numbers of chondrocytes maintain the 
integrity of the tissue. These cells initiate the rapid 
release of proteoglycan from the tissue in response to 
cytokines uch as IL-1 [11] and TNFol [12] but this 
matrix component can be replaced relatively quickly 
[13]. In contrast collagen is much less readily re- 
leased, but when degradation of collagen does occur, 
the structural integrity of the tissue is irreversibly lost 
[14]. Therefore collagen degradation is a key point in 
the control of cartilage turnover. 
Interleukin-4 (IL-4) is a cytokine that was charac- 
terized as a B-cell stimulatory factor and subse- 
quently shown to affect a large number of different 
cell types that include T-cells, macrophages, mono- 
cytes and fibroblasts. It !is produced by T-cells, mast 
cells and basophils and consists of a glycosylated 
protein of 20 kDa [15]. Apart from its immunomodu- 
latory properties it has recently been shown to have a 
number of effects on the production of MMPs. It can 
block the production of collagenase and other MMPs 
by human monocytes [16] and macrophages [17]. In 
addition recent reports suggest hat IL-4 has a pro- 
found effect on bone resorption with demonstrable 
effects on both osteoblasts [18] and osteoclasts [19,20] 
that cause a reduction in bone resorption induced by 
the proinflammatory c tokines. These effects could 
be mediated by a reduction in the levels of secretion 
of cytokines produced by tissue cells [21]. In rheuma- 
toid synovium ex vivo a reduction in the levels of 
IL-6, IL-1/3 and TNFo~ was observed on the addition 
of IL-4 [22] and IL-4 suppressed the secretion of IL-6 
by rheumatoid synovial fibroblasts in culture [23,24]. 
More recently IL-4 has been shown to prevent he 
release of proteoglycan i bovine articular cartilage 
explants [25]. IL-4 has', also been shown to have 
measurable ffects on the synthesis of connective 
tissue matrix proteins upregulating the production of 
both proteoglycan [26] and collagen [27]. 
In a recent study we have shown that combinations 
of IL-1 with either Oncostatin M (OM) or retinoic 
acid [28,29] stimulate the rapid release of proteogly- 
can and collagen from bovine cartilage [30]. In this 
study we show that the release of collagen fragments 
can be prevented by the addition of IL-4 which is 
able to protect cartilage from these mixtures of cy- 
tokines. 
2. Materials and methods 
Chemicals were obtained from the following sup- 
pliers: Human recombinant IL - la  was a generous 
gift from Glaxo Group Research, Greenford, UK. 
Human recombinant Oncostatin M, IL-4 and IL-10 
was obtained from Genzyme, Kent, UK. All other 
chemicals and biochemicals were commercially 
available analytical grade reagents obtained from 
Fisons, Loughborough, UK or BDH, Poole, UK or 
have been previously described [28-30]. 
2.1. Culture medium and test reagents 
Control culture medium was Dulbecco's modifica- 
tion of Eagle's medium containing 25 mM Hepes 
(Gibco) supplemented with glutamine (2 mM), 
streptomycin (100 /zg/ml), penicillin (100 U/ml)  
and amphotericin (2.5 /zg/ml). Interleukin-1 a, IL-4 
and OM were stored a t -70°C and diluted from 
stock solutions into culture medium and used at a 
final concentrations of 1-5 ng ml-~ for IL-1, 2-50 
ng ml- l  for IL-4 and 10-50 ng ml- l  for OM. 
2.2. Cartilage degradation assay 
Bovine nasal septum cartilage from 1-4 animals 
was held at 4°C overnight after slaughter. Discs were 
cut from 2 mm slices to give pieces 2 mm in diame- 
ter and washed twice in HBSS (Gibco) and ran- 
domised. Three discs/well of a 24 well plate were 
incubated at 37°C in control medium (600/zl) for 24 
h. Control medium (600 /zl) with or without test 
reagents (4 wells for each condition) was added and 
the plate incubated at 37°C for 7 days. The supernates 
were harvested and replaced with fresh medium con- 
taining identical test reagents to day 1. The experi- 
ment was continued for a further 7 days and day 7 
and 14 supernates were stored at -20°C until assay. 
To determine the total glycosaminoglycan (GAG) 
and hydroxyproline (OHPro) content of the cartilage 
fragments, the remaining cartilage was digested with 
papain (4.5 mg/ml;  Sigma) in 0.1 M phosphate 
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buffer, pH 6.5, containing 5 mM EDTA and 5 mM 
cysteine hydrochloride, incubating at 65°C until di- 
gestion was complete (16 h). Human skin and syn- 
ovial fibroblasts were cultured as described [35]. 
inhibition calculated. One unit of collagenase activity 
degrades 1 ~g of collagen per minute at 37°C and 1 
U of inhibitory activity inhibits 2 U of collagenase by 
50%. 
2.3. Proteoglycan degradation and collagen degrada- 
tion 
Media samples and papain digests were assayed 
for sulphated glycosaminoglycans (a a measure of 
proteoglycan release) using a modification of the 
1,9-dimethylmethylene blue dye binding assay [31]. 
Sample or standard (40 /~1) was mixed with dye 
reagent (250/xl) in the well of a microtitre plate, and 
the absorbance at 525 nm determined immediately. 
Chondroitin sulphate from shark fin (5 - 40/xg/ml)  
was used as a standard. The complex formed with 
1,9-dimethylmethylene blue results in a decrease in 
absorbance at 525 nm. Hydroxyproline release was 
assayed (as a measure of collagen degradation) using 
a microtitre plate modification of the method in [32]. 
Chloramine T (7% (w/v)) was diluted 1:4 in 
acetate-citrate buffer (57 g sodium acetate, 37.5 g 
tri-sodium citrate, 5.5 g citrate acid, 385 ml propan- 
2-ol/1 water). P-Dimethylaminobenzaldehyde (DAB; 
20 g in 30 ml 60% perchloric acid) was diluted 1:3 in 
propan-2-ol. Specimens were hydrolysed in 6 M HC1 
for 20 h at 105°C and the hydrolysate neutralised by 
drying over NaOH in vacuo, using a Savant speed 
vac. The residue was dissolved in water and 40 /zl 
sample or standard (hydroxyproline; 5-30 /zg/ml) 
added to microtitre plates together with chloramine-T 
reagent (25 /zl) and then DAB reagent (150 ~1) after 
4 min. The plate was heated to 60°C for 35 min, 
cooled and the absorbance at 560 nm determined. 
2.4. Enzyme and inhibitor assays 
3H-acetylated collagen was used to measure col- 
lagenolytic activity by the diffuse fibril assay [33]. 
Aminophenyl mercuric acetate (APMA) was added at 
a concentration f 0.7 mM to activate procollagenase. 
Assays without APMA gave an estimate of active 
collagenase whilst inclusion of APMA allowed total 
collagenase (active + procollagenase) levels to be 
measured. Inhibitory activity was assayed by the 
addition of samples to a known amount of active 
collagenase in the diffuse fibril assay and the % 
2.5. SDS-PAGE and Western blotting 
Samples containing collagenase were separated by 
SDS-PAGE [34] and the separated protein transferred 
to nitrocellulose and then probed with rabbit anti-hu- 
man MMP-1 IgG or rabbit anti-human MMP-13 IgG 
followed by horseradish peroxidase-conjugated swine 
antirabbit IgG. Colour was developed using metal 
enhanced diaminobenzidine tetrahydrochloride 
(Pierce, UK). 
3. Results 
3.1. The effect of IL-4 on the release of GAG and 
collagen fragments from bovine nasal cartilage 
treated with IL-1 or IL-1 + OM 
Previous studies have shown that OM and IL-1 
together stimulate the release of collagen fragments 
from bovine nasal cartilage in culture on day 14 [28]. 
In this study we have used this combination of 
cytokines to rapidly and reproducibly stimulate colla- 
gen release from cartilage. The effect on collagen 
release in response to IL-1 alone or IL-1 in combina- 
tion with OM could be blocked when incubations 
were made in the presence of IL-4 at 50 ng ml-  
(Fig. 1). IL-4 also partially inhibited the release of 
GAG fragments by IL-1 alone but was unable to 
prevent GAG release induced by IL-1 + OM at day 7 
(Fig. 1). The effect on collagen release at day 14 was 
dose dependent with complete inhibition at concen- 
trations of 10 ng ml-1 of IL-4 but little inhibition at 
2 ng ml -l  (Fig. 2). No effect was seen when IL-10 
was added to the cartilage cultures in place of IL-4; 
I1-10 was unable to prevent he release of collagen 
from the tissue (Fig. 3). 
3.2. Analysis of medium from IL-1 + OM and IL-1 + 
OM/IL-4 treated cartilage for collagenase and 
TIMP- 1 
When medium from IL-1, IL-1 + OM and IL-1 + 
OM + IL-4 treated samples were assayed for col- 
100. 
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Fig. 1. The effect of IL-1 in combination with OM either with or 
without IL-4 on the release of GAG and collagen fragments from 
bovine nasal cartilage. Discs of bovine nasal cartilage from 1-4 
animals were cultured 3 discs per well in quadruplicate wells in 
600 Ixl of medium alone with IL-1, IL-1 +OM with and without 
IL-4 for day 0-7 and the media removed. IL-1 concentrations 
were 5 ng ml- l  and OM and IL-4 were added at 50 ng m1-1. 
Each well was replenished with the same medium. At fourteen 
days all medium was removed and the remaining cartilage di- 
gested with papain. The levels of GAG and OH-proline released 
into the medium on day 7 and 14 was measured and the results 
are expressed as % of total released. Results are expressed as 
mean+SD. ~**  P<0.001; **  P<0.0 I ;  * P<0.05 by one 
way analysis of variance (ANOVAR). 
lagenolytic enzymes and the MMP inhibitor TIMP 
we could show that collagenase levels were stimu- 
lated with either IL-1 treatment or OM + IL-1 treated 
samples at day 14 but little collagenolytic activity, 
either active or proenzyme could be demonstrated in 
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Fig. 2. The effect of IL-4 at different concentrations on the 
release of collagen fragments from cytokine treated cartilage. 
Cartilage was incubated as described in Fig. 1 with IL-1, IL-I + 
OM either with and without IL-4 at 50, 10 and 2 ng ml-].  
Results were calculated and expressed as in Fig. 1. 
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Fig. 3. The effect of IL-4 and IL-10 on the release of collagen 
from bovine nasal cartilage treated with IL-1. Cartilage was 
incubated as described in Fig. 1 with IL-1 at 5 ng/ml either with 
or without IL-4 at 50 ng/ml or IL-10 at 50 ng ml -].  Results 
were calculated and expressed as in Fig. 1. 
the IL-1 + OM + IL -4  treated samples  (Fig.  4). In 
this exper iment  most  of  the co l lagenase was found to 
be in act ive form. In most  exper iments  only 30-40% 
of  the total co l lagenase was found to be act ive (data 
not shown).  The appearance of  act ive co l lagenolyt ic  
act iv i ty corre lated with the re lease of  co l lagen frag- 
ments.  T IMP levels  were reduced in the IL-1 and 
IL-1 + OM treated cart i lage.  The presence of  IL -4  
increased T IMP levels when present  with IL-1 (Fig.  
5). 
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Fig. 4. The levels of procollagenase and active collagenase 
activity in media samples removed from cartilage cultures at day 
14 after stimulation with IL-1 and OM with and without IL-4. 
Cartilage was incubated and treated as described in Fig. 1, The 
levels of procollagenase and active collagenase r leased into the 
medium on day 14 was measured and the results expressed as U 
ml-~. Mean___ SD. Active collagenase and total collagenase were 
measured as described in Section 2. 
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Fig. 5. The levels of TIMP activity in media samples removed 
from cartilage cultures at day 14 after stimulation with IL-1 and 
OM with and without IL-4. Cartilage was incubated and treated 
as described in Fig. 1. The levels of TIMP released into the 
medium on day 14 was measured and the results expressed as U 
ml -~. Mean + SD. 
3.3. Effect of IL-4 on the production of TIMP by 
connective tissue fibroblasts 
We investigated if IL-4 was able to up-regulate 
TIMP production in connective tissue fibroblasts. No 
consistent effect was seen on TIMP production either 
with or without IL-1 in the synovial and skin fibrob- 
lasts tested (data not shown). 
3.4. Western blotting of culture medium from cy- 
tokine treated cartilage cultures 
Medium from cartilage treated with IL-1, IL-1 + 
OM and IL-1 + OM + IL-4 were separated by SDS- 
Conlrol 
+IL- I+OM+IL-4 
+IL-I+OM 
Standards 
12 3 
Fig. 6. The identification of MMP-1 in explant media samples at 
day 14 by Western blotting. Cartilage was incubated and treated 
as described in Fig. 1. Media samples (1 ml) were precipitated 
with trichioroacetic acid, washed with acetone and resuspended 
in 20 uL SDS-sample buffer. After separation by SDS-gel elec- 
trophoresis amples were blotted onto nitrocellulose and probed 
with MMP-1 or MMP-13 antibodies. Standards: 1 = 106 kDa; 
2 = 80 kDa; 3 = 49.5 kDa. 
PAGE, transferred to nitrocellulose and probed with 
antibodies to fibroblast collagenase (MMP-1). MMP-1 
was up-regulated when IL-1 + OM was added to 
cartilage in culture but in the presence of IL-4 the 
level of MMP-1 was substantially reduced although 
not completely to control levels (Fig. 6). 
4. Discussion 
The loss of the collagen fibrillar network has a 
profound effect on the functional integrity of carti- 
lage and represents the irreversible phase of cartilage 
destruction [14]. Consequently, in our recent studies 
we have investigated the mechanisms of collagen 
release from cartilage [28,30]. The dramatic release 
of collagen fragments we observed in response to a 
number of stimuli corresponded with the appearance 
in the medium of procollagenase with approx, one- 
third of the enzyme converted to the active form. 
This collagenolytic activity is metal dependent and 
MMP-1 was shown to be present by Western blotting 
[28]. 
T-cells play an important role in the initiation and 
maintenance of inflammation within the rheumatoid 
joint [36]. Two main groups of T-cells called T 
helper-1 (TH-1) and T helper-2 (TH-2) cells can be 
distinguished on the basis of their cytokine profiles 
and it is known that the TH-1 cells predominate in
the rheumatoid joint [37]. TH-1 cells produce IL-2 
and IFN T which stimulate synovial macrophages to
release the inflammatory cytokines IL-1 and TNFa. 
These in turn promote the production of degradative 
enzymes including collagenases [9,10] which results 
in cartilage destruction within the joint. Recently it 
has been proposed that the effects of the proinflam- 
matory cytokines are modulated by inhibitory cy- 
tokines such as IL-4 and IL-10 [38]. TH-2 cells 
produce the anti-inflammatory c tokine IL-4 which 
inhibits the production of IL-1 and TNFa [39-41] 
and also stimulates the production of IL-1 receptor 
antagonist from monocytes [42]. IL-4 has recently 
been shown to inhibit bone resorption and suppress 
MMP production by human alveolar macrophages 
and can antagonise the effect of IL-1 on cartilage 
with respect o proteoglycan synthesis and degrada- 
tion [16-20,25,43]. Therefore, we have investigated 
the effect of adding IL-4 to cartilage, induced to 
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resorb with mixtures of cytokines, to investigate if
IL-4 was able to protect cartilage from collagen loss. 
The dramatic reduction in the release of collagen 
fragments illustrates that this cytokine can protect 
cartilage in a similar way to that recently described 
for bone tissue. IL-10, a cytokine that can mimic 
certain actions of IL-4 [38] or synergise with this 
cytokine was not able to protect cartilage although it 
is possible that human IL-10 is not able to act on 
bovine tissue at this concentration. This reduction is 
accompanied by an inhibition of procollagenase r - 
lease suggesting that down regulation of col- 
lagenoloytic activity is an important mechanism in 
cartilage protection. It is known that IL-4 downregu- 
lates MMPs produced by monocytes/macrophages 
and a recent paper showed that stromelysin-1 (MMP- 
3) was down regulated in chondrocytes [44] and 
synovial cells [45]; further work will be needed to 
determine if other connective tissue cells in culture 
respond in the same way and if collagenase is also 
down regulated. Work is in progress with bovine and 
human chondrocytes. 
It is known that MMP-1 is up-regulated [28] when 
cartilage is treated with IL-1 + OM but must then be 
activated before collagen degradation will occur. 
However the exact mechanism of collagenase activa- 
tion is not clear. In some experiments complete acti- 
vation of collagenase h~.d occurred (Fig. 4) whilst in 
other experiments only 30-40% of the collagenase 
was in the active forra (data not shown). Where 
active collagenase was found to be present then 
release of collagen was also observed. When IL-4 
and IL-1 were combined then an increase in the 
amount of TIMP was usually seen. These combina- 
tions are currently being: tested with connective tissue 
cells in culture to see if the results can be reproduced 
in monolayer culture or if this effect is unique to 
cartilage xplant cultures. 
A reduction in the release of proteoglycan has 
been observed before when cartilage was cultured in 
the presence of IFN,/ or TGF/3 [46,47]. These results 
were interpreted as the effect of an agent (IFN~/) that 
down-regulated MMP production or an agent (TGF/3) 
that up-regulated TIMP production. The effect of 
IL-4 in these studies could be a combination of these 
two effects; this agent proves very efficient at pre- 
venting collagen loss. 
These studies give further support o the hypothe- 
sis that cartilage damage is caused when collagenases 
are synthesised and activated, exceed the local con- 
centration of TIMPs and then destroy the collagen 
matrix. Whilst the amounts of collagenase and TIMP 
produced are obviously important activation of pro- 
collagenase must occur when TIMP levels are low 
and insufficient o block the action of the collage- 
nases in order for collagen turnover to proceed. The 
relevance of these studies to the destruction of carti- 
lage collagen in vivo is interesting and this work 
suggests that products of inflammatory cells within 
the diseased joint can have an affect on cartilage 
damage. Whilst the concentrations of IL-4 used in 
these studies are higher than the levels found in vivo 
the prevention of collagen breakdown is likely to 
achieved where local concentrations of IL-4, released 
from cells is found. It is likely that lower concentra- 
tions of IL-4 would be effective in the bovine carti- 
lage studies if bovine IL-4 was available. Further 
studies will determine if other cytokines found within 
the joint can also prevent cartilage damage. 
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